Clinical Trial Detail

NCT ID NCT04208958
Title Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer (Consortium-IO)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Vedanta Biosciences, Inc.
Indications

Advanced Solid Tumor

colorectal cancer

melanoma

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Nivolumab + Vancomycin + VE800

Age Groups: adult senior

No variant requirements are available.